Quality control of recovered plasma for fractionation: An extensive Italian study

Transfusion

Volumn 48, Issue 7, 2008, Pages 1459-1468

  Liumbruno, Giancarlo Maria ^a   Grazzini, Giuliano ^a   Rossi, Giuseppe ^a   Rafanelli, Daniela ^a   Gambelli, Davide ^a   Farina, Claudio ^a   Mori, Filippo ^a   Zucchelli, Paolo ^a   Marchiori, Giorgio ^a   Breda, Antonio ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD DERIVATIVE;

ARTICLE; BLOOD BANK; BLOOD COMPONENT; BLOOD SAMPLING; BLOOD TRANSFUSION; CONTROLLED STUDY; FRACTIONATION; ITALY; QUALITY CONTROL; BLOOD STORAGE; CHEMISTRY; LABORATORY DIAGNOSIS; METHODOLOGY; PLASMA; STANDARD;

BLOOD PRESERVATION; BLOOD TRANSFUSION; FACTOR VIII; ITALY; PLASMA; QUALITY CONTROL; SPECIMEN HANDLING;

EID: 52049111879     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01709.x     Document Type: Article

References (44)

1. Farrugia A. Plasma for fractionation: safety and quality issues. Haemophilia 2004;10:334-40.
2. Allain JP, Friedli H, Morgenthaler JJ, Pflugshaupt R, Gunson HH, Lane RS, Myllyla G, Rock GA, Schorr JB, Menache-Aronson D, Stryker MH, Woods KR, Surgenor DM. International forum: what are the critical factors in the production and quality control of frozen plasma intended for direct transfusion or for fractionation to provide medically needed labile coagulation factors? Vox Sang 1983;44:246-59.
3. Carlebjörk G, Blombäck M, Akerblom O. Improvement of plasma quality as raw material for factor VIII:C concentrates. Vox Sang 1983;45:233-42.
4. Kakaiya RM, Morse EE, Panek S. Labile coagulation factors in thawed fresh frozen plasma prepared by two methods. Vox Sang 1984;46:44-6.
5. Monograph of human plasma for fractionation (plasma humanum ad separationem) 01/2005:0853, corrected. Strasbourg: European Pharmacopeia; 2005.
6. Farrugia A, Hill R, Douglas S, Karabagias K, Kleinig A. Factor VIII/von Willebrand factor levels in plasma frozen to -30°C in air or halogenated hydrocarbons. Thromb Res 1992;68:97-102.
7. Riggert J, Mörsdorf S, Pindur G, Köhler M, Seyfert UT. Quality of fresh-frozen plasma during storage. Vox Sang 1997;73:257.
8. Myllyla G. Factors determining quality of plasma. Vox Sang 1998;74(Suppl 2):507-11.
9. Hellstern P, Bach J, Haubelt H, Hitzler WE, Mathis S, Vogt A. The impact of the intensity of serial automated plasmapheresis and the speed of deep-freezing on the quality of plasma. Transfusion 2001;41:1601-5.
10. Hellstern P, Haubert H. Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. Thromb Res 2002;107(Suppl 1):S3-8.
11. Ben-Tal O, Zwang E, Eichel R, Badalbev T, Hareuveni M. Vitamin K-dependent coagulation factors and fibrinogen levels in FFP remain stable upon repeated freezing and thawing. Transfusion 2003;43:873-7.
12. Burnouf T, Kappelsberger C, Frank K, Burkhardt T. Protein composition and activation markers in plasma collected by three apheresis procedure. Transfusion 2003; 43:1223-9.
13. Kretzschmar E, Kruse F, Greiss O, Paunovic D, Kallweit T, Trobisch H. Effects of extended storage of whole blood before leukocyte depletion on coagulation factors in plasma. Vox Sang 2004;87:156-64.
14. Runkel S, Haubelt H, Hitzler W, Hellstern P. The quality of plasma collected by automated apheresis and of recovered plasma from leukodepleted whole blood. Transfusion 2005; 45:427-32.
15. Swärd-Nilsson AM, Persson PO, Johnson U, Lethagen S. Factors influencing factor VIII activity in frozen plasma. Vox Sang 2006;90:33-9.
16. Preston AE, Barr A. The plasma concentration of factor VIII in the normal population. The effect of age, sex and blood group. Br J Haematol 1964;10:238-45.
17. McCallum CJ, Peake IR, Newcombe RG, Bloom AL. Factor VIII levels and blood group antigens. Thromb Haemost 1983;50:757.
18. Mohanty D, Ghosh K, Marwaha N, Kaur S, Chauhan AP, Das KC. Major blood group antigens: a determinant of factor VIII levels in blood? Thromb Haemost 1984;51: 414.
19. Ørstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 1985;37:89-101.
20. Souto JC, Almasy L, Muòiz-Diaz E, Soria JM, Borrell M, Bayén L, Mateo J, Madoz P, Stone W, Blangero J, Fontcuberta J. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol 2000;20:2024-8.
21. Moeller A, Weippert-Kretschmer M, Prinz H, Kretschmer V. Influence of ABO blood groups on primary hemostasis. Transfusion 2001;41:56-60.
22. O'Donnell J, Laffan MA. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med 2001;11:343-51.
23. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol 2002;22: 335-41.
24. Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L. Cross-laboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors. Blood Coagul Fibrinolysis 2005;16:597-605.
25. Select Committee on Quality Assurance in Blood Transfusion Services. Guide to the preparation, use and quality assurance of blood components. 13th ed. Strasbourg, France: Council of Europe Publishing; 2007.
26. Italian Ministry of Health. Decree of March 3rd, 2005. Characteristics and modalities for blood and blood components donation. Gazzetta Ufficiale della Repubblica Italiana n. 85, April 13th, 2005.
27. Piazza A, Olivetti E, Barbanti M, Reali G, Domenici R, Giari A, Benciolini P, Caenazzo L, Cortivo P, Sestetti A, Bonavita V, Crino C, Pascali V, Fiori A, Bargagna M. The distribution of some polymorphisms in Italy. Gene Geogr 1989;3:69-139.
28. Girma JP, Fressinaud E, Houllier A, Laurian Y, Amiral J, Meyer D. Assay of factor VIII antigen (VIII:Ag) in 294 haemophilia A patients by a new commercial ELISA using monoclonal antibodies. Haemophilia 1998;4:98-103.
29. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Expert Working Group. Guideline for industry. Text on validation of analytical procedures. ICH- Q2A. March 1995. Available from: URL: http://www.fda.gov/cder/Guidance/ichq2a.pdf
30. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Expert Working Group. Guidance for industry. Validation of analytical procedures: methodology. ICH-Q2B. November 1996. Available from: URL: http://www.fda.gov/cder/Guidance/ 1320fnl.pdf
31. Italian Republic. Law n. 219 of October 21st, 2005. New discipline of transfusion medicine activities and national production of blood derivatives. Gazzetta Ufficiale della Repubblica Italiana n. 251, October 27th, 2005.
32. Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003: setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components, and amending Directive 2001/83/EC. Official Journal of the European Union 2003;8/2/2003:L 33/30-40.
33. Robinson EAE. The European Union Blood Safety Directive and its implications for blood services. Vox Sang 2007;93: 122-30.
34. Commission Directive 2004/33/EC of 2 March 2004: implementing certain technical requirements for blood and blood components. Off J Eur Union 2004;30/3/2004:L 91/25-39.
35. Smith JF, Ness PM, Moroff G, Luban NLC. Retention of coagulation factors in plasma frozen after extended holding at 1-6°C. Vox Sang 2000;78:28-30.
36. Gabra GS, Prowse CV, Boulton FE. Importance of a quality assurance scheme for factor VIII assays in quality monitoring of human plasma destined for fractionation into factor VIII concentrate. Vox Sang 1989;56:65-70.
37. Raut S, Sands D, Heat AB, Barrowcliffe TW. Variability in factor VIII concentrate measurement: results from SSC field collaborative studies. J Thromb Haemost 2003;1:1927- 34.
38. Rosen S. A rebuttal: issues with the assay of factor VIII activity in plasma and factor VIII concentrates. Thromb Haemost 2001;86:1132-3.
39. Hubbard AR, Bevan SA, Weller LJ. Potency estimation of recombinant factor VIII: effect of assay method and standard. Br J Haematol 2001;113:533-6.
40. van den Besselaar AM, Haas FJ, Kuypers AW. Harmonisation of factor VIII:C assay results: study within the framework of the Dutch project "Calibration 2000." Br J Haematol 2006;132:75-9.
41. Cinotti S, Paladino E, Morfini M. Accuracy of FVIII:C assay by one-stage method can be improved using hemophilic plasma as diluent. J Thromb Haemost 2006;4:828-33.
42. Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Hemost 2002;28:247-56.
43. Mazurier C, Parquet-Gernez A, Goudemand M. Validation of a procedure for potency assessing of a high purity factor VIII concentrate: comparison of different factor VIII coagulant assays and effect of prediluent. Thromb Haemost 1990;64:251-5.
44. Lin Y, Yang X, Chevrier MC, Craven S, Barrowcliffw TW, Lemieux R, Ofosu FA. Relationships between factor VIII:Ag and factorVIII in recombinant and plasma-derived factor VIII concentrates. Haemophilia 2004;10:459-69.